FY25's ₹8 Cr profit never converted to cash, and Q2 FY26 has already gone operating-loss.

• Earnings aren't cashing. FY25 operating cash flow was ₹2 Cr on ₹8 Cr reported PAT — a 0.25× conversion. Free cash flow was negative ₹7 Cr in FY24 and ₹10 Cr in FY25 despite the return to book profit.
• Working capital ate the profit. Debtor days moved 35 → 79 → 89 → 114 over three years; cash conversion cycle flipped from −5 days to +97. That 160-day swing absorbed roughly ₹65 Cr of cash that would otherwise have been FCF.
• Q2 FY26 broke the narrative. Sep-25 printed a ₹2.5 Cr operating loss at 13% higher revenue than the prior quarter; Dec-25 recovered only to 5.4% OPM. After five profitable quarters, the trend reversed before the market priced it.

Read as an Ipca restructuring vehicle, not a Gandhi-family compounder.

• Ipca, not Gandhi. The 58% promoter block is Ipca Laboratories 41% plus Gandhi-family and allied entities ~17%. Control swung in 2022 when Ipca completed a 26.57% open offer and then stair-stepped up through two warrant rounds at ₹139.50.
• Real cash, real commitment. Ipca has converted 50 lakh warrants at ₹139.50 — roughly ₹70 Cr of hard cash against today's ₹60 market price. That money funded the debt paydown and the new lyophilization line, not operating cash flow.
• The trade-off. Ipca is also a customer — ₹26 Cr of FY25 sales (~20% of revenue), rising from 11% in FY22. If related-party revenue crosses 25–30%, this is a captive contract manufacturer and should be valued against Ipca's multiples, not the peer group.

A clean balance sheet sitting on top of a still-sub-scale, still-lumpy P&L.

The balance sheet is the bull case — borrowings down from ₹163 Cr to ₹39 Cr, D/E 0.38×, interest cost collapsed from ₹26 Cr in FY21 to ₹2 Cr. But the deleveraging was funded by Ipca's ₹36 Cr equity infusion in FY25, not by operations. Strip the FY22 outlier and four post-crisis years produced ₹22 Cr of OCF on ₹428 Cr of revenue — a 5% cash margin. The thesis lives or dies on whether the new lyophilization line fills and receivables compress.

A C-grade board where minority protection rests on Ipca's self-interest, not board independence.

• Pay is not earned. CEO Kunal Gandhi was paid ₹5.27 Cr in FY25 — 64% of the ₹8.2 Cr standalone PAT and 109× median employee. A 48% YoY raise in a near-breakeven year, with a ₹1.40 Cr leave-encashment lump sum inside the number.
• Independence is nominal. Three of seven directors are genuinely independent; one 'non-executive' is literally an executive director of the 41% shareholder. Audit committee includes the CEO. The CFO owns 1,050 shares after a 43-year tenure.
• Two off-filing signals. Both Gandhi promoters settled a SEBI case in March 2023 for ₹3.07 lakh; BSE flagged an unexplained price move on 8 April 2026, the same day the Lyka Exports merger went effective. Neither is in the annual report.

Near-death → outlier rescue year → a turnaround still waiting for cash.

Before. By FY20 Lyka had lost the founder, posted a ₹63 Cr loss, and had its bank debt assigned to an Asset Reconstruction Company. Equity reserves were negative ₹43 Cr. A preferential issue to the Gandhi promoters failed because a pledgee refused consent.

Pivot. In January 2022 Ipca Laboratories announced a 26.57% open offer. FY22 then delivered revenue of ₹194 Cr at 52% OPM and ₹38 Cr PAT — numbers that were never achieved before and have never been achieved since. Management later disclosed the profit came from 'higher-realization products' that were never named.

Today. Two warrant rounds have lifted Ipca to 41%, debt is ₹39 Cr, and a new lyophilization line is capitalized. But Q2 FY26 operating margin is −6.9%, receivables stretched to 114 days, and the stock has round-tripped through a 78% drawdown. FY26 annual results in May–June will settle whether the FY22 event or the FY25 event is the base case.